Background We sought to evaluate the impact of adjuvant chemotherapy on overall survival (OS) in patients with stage I endometrioid epithelial ovarian cancer (EEOC) or ovarian clear cell cancer (OCCC) using a national database. Patients and methods The Surveillance, Epidemiology, and End Results database was used to identify patients diagnosed with International Federation of Gynecology and Obstetrics (FIGO) stage I EEOC or OCCC from 2000 to 2013. We sought to identify predictors of chemotherapy use and to assess the impact of chemotherapy on OS in these patients. OS was compared using the log-rank test and the Cox proportional hazards model. Results In all, 3552 patients with FIGO stage I EEOC and 1995 patients with stage I OCCC were identified. Of the 1600 patients (45%) with EEOC who underwent adjuvant chemotherapy, the 5-year OS rate was 90%, compared with 89% for those who did not undergo adjuvant chemotherapy (P = 0.807). Of the 1374 (69%) patients with OCCC who underwent adjuvant chemotherapy, the 5-year OS rate was 85%, compared with 83% (P = 0.439) for those who did not undergo adjuvant chemotherapy. Chemotherapy use was associated with younger age, higher substage, and more recent year of diagnosis for both the EEOC and OCCC groups. Only in the subgroup of patients with FIGO substage IC, grade 3 EEOC (n = 282) was chemotherapy associated with an improved 5-year OS-81% compared with 62% (P = 0.003) in untreated patients (HR: 0.583; 95% CI: 0.359-0.949; P = 0.030). In patients with OCCC, there was no significant effect of adjuvant chemotherapy on OS in any substage. Conclusions Adjuvant chemotherapy was associated with improved OS only in patients with substage IC, grade 3 EEOC. In stage I OCCC, adjuvant chemotherapy was not associated with improved OS.

中文翻译：

---

铂时代 I 期子宫内膜样癌或透明细胞卵巢癌患者的辅助化疗：一项监测、流行病学和最终结果队列研究，2000-2013。

背景 我们试图使用国家数据库评估辅助化疗对 I 期子宫内膜样上皮性卵巢癌 (EEOC) 或卵巢透明细胞癌 (OCCC) 患者的总生存期 (OS) 的影响。患者和方法 监测、流行病学和最终结果数据库用于识别从 2000 年到 2013 年被诊断为国际妇产科联合会 (FIGO) I 期 EEOC 或 OCCC 的患者。我们试图确定化疗使用的预测因子并评估化疗对这些患者 OS 的影响。使用对数秩检验和 Cox 比例风险模型比较 OS。结果 总共确定了 3552 名FIGO I 期EEOC 患者和1995 名I 期OCCC 患者。在接受辅助化疗的 1600 名 EEOC 患者（45%）中，5 年 OS 率为 90%，相比之下，未接受辅助化疗的患者为 89%（P = 0.807）。在接受辅助化疗的 1374 例（69%）OCCC 患者中，5 年 OS 率为 85%，而未接受辅助化疗的患者为 83%（P = 0.439）。对于 EEOC 和 OCCC 组，化疗的使用与更年轻、更高亚阶段和更近一年的诊断有关。仅在FIGO亚期IC患者亚组中，3级EEOC（n = 282）与未治疗患者的5年OS-81%相比，化疗与改善5年OS-81%相关（P = 0.003）（HR：0.583；95） % CI：0.359-0.949；P = 0.030)。在 OCCC 患者中，辅助化疗对任何亚阶段的 OS 均无显着影响。结论 辅助化疗仅与 IC 亚期 3 级 EEOC 患者的 OS 改善相关。